DDInter1438 DDInter1840
Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during urination. In the USA, this drug was previously marked by Roche but has been discontinued by the FDA. It is still used in various parts of the world. Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Phenazopyridine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Phenazopyridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Clofarabine {u} (Compound) causes {v} (Side Effect) Mediastinal disorder
Mediastinal disorder {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Phenazopyridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cocaine
Cocaine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Trabectedin
Phenazopyridine {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Phenazopyridine {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Phenazopyridine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Phenazopyridine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Trabectedin (Compound)
Phenazopyridine may cause a moderate interaction that could exacerbate diseases when taken with Cocaine and Cocaine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Trabectedin (Compound)
Phenazopyridine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Phenazopyridine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Trabectedin (Compound)